SEC Comment Letter 0000000000-23-006629 to Biodexa Pharmaceuticals Plc (BDRX)
Biodexa Pharmaceuticals Plc
Date: June 21, 2023 · CIK: 0001643918 · Accession: 0000000000-23-006629
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-272693
Letter
United States securities and exchange commission logo June 21, 2023 Stephen Stamp Chief Executive Officer Biodexa Pharmaceuticals Plc 1 Caspian Point Caspian Way Cardiff, CF10 4DQ, United Kingdom Re:Biodexa Pharmaceuticals Plc Registration Statement on Form F-1 Filed June 16, 2023 File No. 333-272693 Dear Stephen Stamp: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Jason Drory at 202-551-8342 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Alice Hsu
Show Raw Text
United States securities and exchange commission logo
June 21, 2023
Stephen Stamp
Chief Executive Officer
Biodexa Pharmaceuticals Plc
1 Caspian Point
Caspian Way
Cardiff, CF10 4DQ, United Kingdom
Re:Biodexa Pharmaceuticals Plc
Registration Statement on Form F-1
Filed June 16, 2023
File No. 333-272693
Dear Stephen Stamp:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Jason Drory at 202-551-8342 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc: Alice Hsu